# 🫘 Acute Kidney Injury (AKI)

## 🔄 AKI-AKD-CKD Continuum

![AKI to CKD Continuum showing progression from acute injury through acute kidney disease to chronic kidney disease](https://urinenephrology.org/2025_UDPA_Lectures_Live/assets/AKI_CKD.png)

Modern understanding recognizes kidney disease as a continuum rather than discrete categories, with acute kidney disease (AKD) serving as the bridge between acute injury and chronic disease.

### 📋 Acute Kidney Disease (AKD) — Formal Definition (KDIGO 2026 draft)

**AKD** is defined as any of the following persisting for **≤3 months**:

- AKI (functional or structural criteria)
- GFR \<60 mL/min/1.73m²
- GFR decrease ≥35 mL/min from baseline
- SCr increase \>50%
- Markers of kidney damage (albuminuria, hematuria, leukocyturia)

**Clinical Pearl:** AKD *without* AKI should be differentiated from AKD *following* AKI — they have different underlying causes and management strategies.

### 🚨 Emergency AKI Recognition Protocol

Time-sensitive evaluation for rapid clinical decision-making

1 **Immediate Assessment**

Vital signs, volume status, bladder scan, 12-lead ECG

- Check for hyperkalemia (peaked T waves)
- Assess hemodynamic stability
- Rule out obstruction first

2 **STAT Laboratories**

BMP, CBC, urinalysis with microscopy, ECG

- Repeat K+ if \>5.5 mEq/L
- Rule out hemolysis
- Check magnesium and phosphorus

3 **Foley Catheter**

If bladder scan \>150mL or unexplained AKI

- May resolve AKI completely
- Check post-void residual
- Monitor urine output closely

4 **Urine Microscopy**

Fresh specimen within 2 hours of collection

- Differentiate prerenal vs intrarenal vs postrenal
- Look for casts, crystals, cells

## 📊 KDIGO AKI Staging (2026 Draft Three-Axis System)

Staging now incorporates **three independent axes**: Serum Creatinine (C), Urine Output (U), and Damage Biomarker (B)

| Stage | Serum Creatinine (C) | Urine Output (U) | Damage Biomarker (B) | Clinical Implications |
|----|----|----|----|----|
| **C0/U0/B1** | No SCr or UOP change | No UOP change | B1 = Positive | **Subclinical AKI** — biomarker-only detection, intervene early |
| **C1/U1** | ≥0.3 mg/dL or 1.5-1.9× baseline | \<0.5 mL/kg/h (ideal BW) for 6-12h | B0 or B1 | Early recognition, identify etiology |
| **C2/U2** | 2.0-2.9× baseline | \<0.5 mL/kg/h for \>12h | B0 or B1 | Increased monitoring, nephrology consult |
| **C3/U3** | ≥3.0× baseline, OR ≥4.0 mg/dL, OR RRT | \<0.3 mL/kg/h for \>24h OR anuria \>12h | B0 or B1 | Consider RRT, ICU monitoring |

**KDIGO 2026 draft — Cystatin C Alternative:** Serum cystatin C (≥1.5× baseline within 7 days) is proposed as an alternative functional criterion in the public-review draft when SCr is unreliable (low muscle mass, liver disease, extremes of body size). **New in 2026 — Three-Axis Classification:** The three-axis system allows classification by any combination of available measurements. A patient can be staged as **C0/U0/B1** (subclinical AKI detected only by biomarkers) — this represents a major paradigm shift enabling earlier intervention.

### ⏲ Transient vs. Persistent AKI (KDIGO 2026 draft)

| Category           | Definition                                         |
|--------------------|----------------------------------------------------|
| **Transient AKI**  | ≤48h increase in SCr or cystatin C, or reduced UOP |
| **Persistent AKI** | \>48h and up to 7 days                             |

**Clinical Significance:** Persistent AKI carries worse prognosis and warrants more aggressive monitoring and intervention.

### 🔁 Recurrent AKI (KDIGO 2026 draft)

Recurrent AKI is defined as a **new episode after partial or complete resolution** of a previous episode. Recurrent AKI confers additional risk for **CKD progression** and **cardiovascular mortality**, and should prompt evaluation for modifiable risk factors and closer long-term follow-up.

### 📐 Baseline SCr Selection — Hierarchical Approach (KDIGO 2026 draft Figure 1)

1 **Representative outpatient value** \<365 days before admission 2 **Admission value** (unless AKI suspected on admission) 3 **Lowest value during admission** (when not on RRT) 4 **Estimate via CKD-EPI** assuming eGFR 75 mL/min/1.73m² **Clinical Pearl:** Use the highest-priority available value. Estimating baseline from eGFR 75 is a last resort and tends to overestimate AKI incidence in patients with pre-existing CKD.

## 🧐 Critical Concept: Why eGFR is Invalid in AKI

**Fundamental Principle:** eGFR calculations are only valid when serum creatinine is at steady state

### 🔴 AKI: Rising Creatinine = Invalid eGFR

- **Creatinine Status:** Rapidly rising (non-steady state)
- **eGFR Validity:** ❌ INVALID - significantly overestimates true GFR
- **Clinical Reality:** True GFR may be near zero while eGFR still appears "normal"
- **Time to Steady State:** 3-5 days after GFR change
- **Clinical Use:** Monitor creatinine trends, not absolute eGFR values

### 🟢 CKD: Stable Creatinine = Valid eGFR

- **Creatinine Status:** Stable over months (steady state)
- **eGFR Validity:** ✅ VALID - accurately reflects true GFR
- **Clinical Reality:** eGFR closely approximates measured GFR
- **Time Course:** Gradual changes over months to years
- **Clinical Use:** Staging, monitoring, medication dosing

### 🧬 The Total Nephrectomy Teaching Example

**Scenario:** Patient undergoes total nephrectomy (both kidneys removed)

#### ⚡ Immediate Reality (Time = 0)

- **True GFR:** 0 mL/min (no kidneys!)
- **Serum Creatinine:** Still normal (1.0 mg/dL)
- **Calculated eGFR:** ~90 mL/min (completely wrong!)
- **Clinical Status:** Patient is anuric, requires emergency dialysis

#### 🕰️ Day 1 Post-Op

- **True GFR:** Still 0 mL/min (unchanged)
- **Serum Creatinine:** 2.0 mg/dL (rising)
- **Calculated eGFR:** ~38 mL/min (still way off!)
- **Clinical Status:** Same - still requires dialysis

#### 📈 Day 2 Post-Op

- **True GFR:** Still 0 mL/min (unchanged)
- **Serum Creatinine:** 3.5 mg/dL (continuing to rise)
- **Calculated eGFR:** ~20 mL/min (getting closer but still wrong)
- **Clinical Status:** Same - still requires dialysis

#### 📊 Day 3 Post-Op

- **True GFR:** Still 0 mL/min (unchanged)
- **Serum Creatinine:** 5.0 mg/dL (continuing upward)
- **Calculated eGFR:** ~13 mL/min (improving but still overestimating)
- **Clinical Status:** Same - still requires dialysis

#### 🎯 Steady State (Days 4-5)

- **True GFR:** Still 0 mL/min (unchanged)
- **Serum Creatinine:** Plateaus (8-12 mg/dL)
- **Calculated eGFR:** ~5-7 mL/min (finally approaching reality)
- **Clinical Status:** Same - chronic dialysis needed

#### 💡 Key Teaching Points

- **GFR changed instantly** (0 mL/min immediately after surgery)
- **Creatinine rises gradually** over 3-5 days to reach new steady state
- **eGFR "catches up" slowly** and significantly lags behind true GFR changes
- **Clinical decisions must be based on the clinical scenario,** not misleading eGFR values
- **In AKI, trend and absolute creatinine values matter more than calculated eGFR**

### 🎯 Clinical Applications in AKI Management

#### ❌ Don't Rely On:

- eGFR values during rising creatinine
- "Normal" eGFR in early AKI
- eGFR for medication dosing in AKI
- eGFR for dialysis timing decisions

#### ✅ Instead Focus On:

- Absolute creatinine values and trends
- KDIGO staging criteria
- Clinical signs: urine output, volume status
- Time course and rate of creatinine rise

#### 👥 Patient Education:

- Explain why eGFR seems "better" than reality
- Focus on kidney function recovery, not numbers
- Emphasize clinical improvement markers
- Avoid false reassurance from "improving" eGFR

#### ⚠️ Common Clinical Errors to Avoid

- **"The eGFR is still 45, so the kidneys are working okay"** - Wrong! In AKI, this could represent severe kidney injury
- **Using eGFR for medication dosing in AKI** - Can lead to significant overdosing
- **Reassuring patients based on "stable" eGFR** - While creatinine is still rising
- **Delaying nephrology consultation** - Because eGFR "doesn't look that bad"
- **Comparing AKI eGFR to CKD staging** - Fundamentally different clinical contexts

STOP

### Do NOT Use the eGFR from the BMP for Drug Dosing in AKI

The eGFR printed on your BMP is a **steady-state equation (CKD-EPI)**. It is **only valid when creatinine is stable**. When creatinine is actively rising, that number **OVERESTIMATES true GFR** — potentially by a massive margin. A patient whose Cr jumped from 1.0 to 2.0 in 24 hours may have a true GFR near zero, but the BMP prints **“eGFR 38”** — this is **WRONG**.

**💊 Inappropriate Drug Dosing**

Overdosing of renally cleared drugs because the “eGFR looks okay”

**💤 False Reassurance**

“The eGFR is 45, kidneys are fine” — while GFR may actually be near zero

**⏰ Delayed Nephrology Consultation**

Consult deferred because the eGFR “doesn't look that bad”

### ✅ Kinetic eGFR (KeGFR) — A Better Estimate, But Not a Magic Number

KDIGO 2026 draft Rec 2.3.2 (2B) The KDIGO 2026 draft proposes calculating kinetic eGFR (KeGFR) in hospitalized adults when a non-steady-state GFR estimate is needed.

KeGFR accounts for the rate of creatinine change, providing a more accurate real-time GFR estimate during AKI:

**📐 How It Works**

- Uses the rate of SCr rise (ΔCr/Δtime) to estimate true GFR
- More accurate than steady-state eGFR when creatinine is rapidly changing

**🏥 Clinical Applications**

- Useful for drug dosing decisions in AKI
- Valuable for assessing AKI recovery trajectory

#### ⚠️ KeGFR Caveats — Evidence Is Limited

- The evidence base is **small** — limited validation studies, no large RCTs confirming KeGFR-guided decisions improve outcomes
- The formula **assumes stable creatinine production**, which is NOT true in:
  - **Sepsis** — altered muscle metabolism
  - **Muscle wasting / critical illness** — reduced Cr generation
  - **Rhabdomyolysis** — massive Cr release from muscle
  - **Large volume resuscitation** — dilutional effects
- KDIGO grades this **2B** — a weak recommendation with moderate certainty

#### 🎯 The More Important Clinical Lesson

**You do not need to calculate KeGFR at the bedside.** What you DO need to do is **IGNORE the eGFR on the BMP when creatinine is changing.**

**The TREND IS the GFR estimate.** A rising creatinine = GFR is lower than any equation tells you. A falling creatinine = GFR is recovering. Use **clinical judgment and creatinine trends** for drug dosing — not the number the lab prints.

❌ Do NOT

Dose vancomycin, aminoglycosides, or DOACs based on the eGFR printed on a BMP when Cr is rising

✅ DO

Use creatinine trajectory + clinical context. When in doubt, dose for a lower GFR than the equation suggests.

## 🔍 Systematic Diagnostic Approach

### 🔬 Urine Microscopy: The Key Differentiator

Fresh urine microscopy within 2 hours provides critical diagnostic information

#### 💧 Prerenal AKI

**Microscopy:** Hyaline casts Concentrated Rare RTEs Minimal cells **Labs:** FENa \<1% • UOsm \>500 • BUN:Cr \>20:1

#### 🔥 Intrarenal AKI

**Microscopy by Type:**

|     |                            |
|-----|----------------------------|
| ATN | Muddy brown casts, RTEs    |
| GN  | RBC casts, dysmorphic RBCs |
| AIN | WBC casts, sterile pyuria  |

**Labs:** FENa \>2% • UOsm ~300 • Isosthenuria

#### 🚰 Postrenal AKI

**Microscopy:** Variable findings RBCs (stones) WBCs (infection) Crystals **Imaging:** Urgent US • CT if indicated

#### 🔊 Kidney Doppler Ultrasound & RRI

Measurement of renal resistive index (RRI) may aid in risk stratification for AKI progression and severity, particularly in critically ill populations.

**PP 2.5.8:** RRI for AKI risk stratification **PP 2.5.9:** POCUS for volume assessment **Clinical Use:** POCUS may assist in distinguishing volume-responsive from intrinsic AKI

#### 🛡️ Kidney Functional Reserve

Assessment of kidney functional reserve before a potential nephrotoxic exposure may help identify patients at increased risk of developing AKI.

**PP 2.3.1:** Evaluate kidney functional reserve in at-risk patients **Key Applications:** Pre-surgical risk assessment, pre-contrast evaluation, nephrotoxic drug planning

## ⚠️ FeNa and FeUrea — Know Their Limits

These are commonly over-relied-upon tests. Understand exactly what they can and cannot tell you.

### The ONLY Clinical Question FeNa Reliably Answers

**In the oliguric patient: is this prerenal (hemodynamic) AKI or ATN?**

That is the narrow clinical scenario where FeNa has reasonable diagnostic performance. Outside of this context, FeNa adds little to clinical decision-making.

### 🚫 Even for This Narrow Question, FeNa Is Confounded By:

**Diuretics**

Renders FeNa **uninterpretable** — increases urinary Na regardless of volume status

**CKD**

Elevated baseline FENa due to impaired tubular reabsorption — prerenal AKI may have FeNa \>1%

**Sepsis**

FeNa can be **low despite intrinsic injury** — sepsis-associated AKI has mixed hemodynamic and tubular features

**Contrast Exposure**

Contrast-associated AKI can present with low FeNa, mimicking prerenal disease

**Early Obstruction**

Postrenal AKI can have variable FeNa depending on timing and degree of obstruction

### FeUrea: Not the Fix You Were Promised

FeUrea was proposed to overcome the diuretic limitation of FeNa. However, **diagnostic performance remains poor** — sensitivity and specificity are insufficient for clinical decision-making in most scenarios. FeUrea does not reliably distinguish prerenal from intrinsic AKI in diuretic-treated patients.

**KDIGO 2026 draft (PP 2.5.4):** Fractional excretion of sodium and urea have **"limited overall clinical utility"** — do NOT rely on these as primary diagnostic tools.

### 🔬 Urine Microscopy vs FeNa — Head-to-Head Comparison

GOLD STANDARD

#### 🔬 Urine Microscopy (Fresh Specimen)

- **Muddy brown casts = ATN.** That is the answer.
- RBC casts = glomerulonephritis
- WBC casts = interstitial nephritis
- Hyaline casts = prerenal
- Not confounded by diuretics, CKD, or sepsis
- Provides etiologic diagnosis, not just a number
- **Must be fresh (\<2 hours) for accuracy**

✅

MORE diagnostic information

LIMITED UTILITY

#### 🧮 FeNa Calculation

- Only answers: prerenal vs ATN?
- Uninterpretable with diuretics
- Misleading in CKD baseline
- False low in sepsis, contrast, early obstruction
- Binary output (high vs low) with no etiologic nuance
- FeUrea does not meaningfully improve performance
- **You don't need a calculation when casts give the diagnosis**

⚠️

Commonly over-relied-upon

**💡 Bottom Line:** Urine microscopy with a fresh specimen gives you **MORE diagnostic information than FeNa** in virtually every clinical scenario. Muddy brown granular casts = ATN. That is the answer. You do not need a calculation. Teach yourself to spin a urine — it is the single most underused diagnostic tool in nephrology.

## 🧬 AKI Biomarkers — Now Part of the KDIGO 2026 draft Definition

The KDIGO 2026 draft proposes incorporating structural biomarkers into the AKI definition and staging system (B0/B1 axis). These proposed roles remain subject to revision before final guideline publication; use depends on clinical validation and local availability.

#### 🔬 TIMP-2 × IGFBP7 (NephroCheck)

FDA-Approved

- Cell cycle arrest markers indicating tubular stress
- Best within 12h of ICU admission or after major surgery/sepsis
- Identifies risk of moderate-to-severe AKI
- **Rec 2.4.1** (2B adults, 2C children)

#### 🧪 Urine NGAL

Early Detection

- Identifies high risk of severe AKI in hospital settings
- Upregulated within hours of tubular injury (24-48h before SCr rise)
- Useful in cirrhosis-associated AKI to differentiate ATI vs HRS when clinical features are equivocal

#### 📊 Baseline Albuminuria (UACR)

Risk Stratification

- Offers additional prognostic value beyond eGFR for evaluating AKI risk
- Useful across inpatient and outpatient settings
- Should be checked in all at-risk patients

#### ⚠️ Important: Urine Eosinophils Are NOT Reliable

Urine eosinophils have **LOW sensitivity and LOW specificity** — they cannot rule AIN in *or* out. In the largest series (Muriithi, CJASN 2013; 566 patients with paired urine eosinophil testing and native kidney biopsy) specificity was only 68.2% with a PPV of 15.6%, giving **LR+ 0.97 and LR− 1.01** — likelihood ratios of essentially 1, meaning the result does not move the probability of AIN in either direction. **Do not order urine eosinophils.** Urinary inflammatory cytokines may be more useful for distinguishing AIN.

### 🚨 ANURIA: Nephrological Emergency

**Definition:** Urine output \<100 mL per 24 hours

#### 🫀 Vascular Causes

Bilateral renal artery occlusion Bilateral renal vein thrombosis Acute cortical necrosis

#### 🚰 Obstructive Causes

Bilateral ureteral obstruction Complete urethral obstruction Retroperitoneal fibrosis **Emergency Management:** → Nephrology consult within hours → CT angiography if vascular suspected → Emergency decompression if obstructive → Prepare for urgent dialysis

### 💊 Furosemide Stress Test (FST)

**🏅 Proposed in the KDIGO 2026 public-review draft (Rec 2.3.1, 2B-2C):** Use FST to assess progression risk to Stage 3 AKI, including RRT, in euvolemic/hypervolemic patients with Stage 1-2 AKI.

Revolutionary risk stratification leveraging **tubular secretion** as a functional marker of tubular integrity.

#### 📋 Protocol

|                       |                                              |
|-----------------------|----------------------------------------------|
| Dose (naive)          | 1.0 mg/kg IV push                            |
| Dose (prior exposure) | 1.5 mg/kg IV push                            |
| Timing                | Measure UOP over 2 hours                     |
| Responders            | UOP ≥200 mL/2h → lower risk of progression   |
| Non-responders        | UOP \<200 mL/2h → high risk of Stage 3 / RRT |

#### 🎯 Performance

87% Sensitivity 84% Specificity 0.87 AUC 96% CRRT Prediction **Clinical Pearl:** Non-responders have **2.4× higher likelihood** of requiring CRRT. Can be performed outside ICU settings. **⚠️ Non-responder Action:** UOP \<200 mL/2h → escalate monitoring and consider nephrology consult. Prepare for potential RRT.

## 🔥 Intrinsic Renal Disease: Comprehensive Overview

### ⚡ Rapidly Progressive Glomerulonephritis (RPGN)

**NEPHROLOGIC EMERGENCY:** Rapid kidney function deterioration with extensive crescent formation

#### 📈 Rising Creatinine

→ Days to weeks progression → May double in \<7 days → Rapid deterioration warrants urgent assessment; do not wait for a 50% eGFR loss

#### 🔬 Active Sediment

→ RBC casts (strong clue to glomerular bleeding; may be absent in GN) → Dysmorphic RBCs → Proteinuria \>1g/day

#### ⏰ Clinical Urgency

→ Nephrology consult \<24h → Urgent kidney biopsy → Delay = permanent damage

#### 🧬 Categories (by IF)

|                |                                   |
|----------------|-----------------------------------|
| Anti-GBM       | Linear IgG staining               |
| Immune Complex | Granular (lupus, post-infectious) |
| Pauci-Immune   | ANCA-associated vasculitis        |

#### 🧪 Essential Labs

ANCA (PR3/MPO) Anti-GBM C3, C4, CH50 ANA, anti-dsDNA **⚡ Emergency Management:** Methylprednisolone 500-1000mg IV × 3 days + plasmapheresis (if anti-GBM+) + urgent biopsy

### 🔥 Acute Interstitial Nephritis (AIN)

**Immune-mediated inflammation** of the tubulointerstitium with varied clinical presentations

**⚠️ Classic Triad Myth:** Fever + Rash + Eosinophilia seen in **only 10% of cases!** Most AIN is subtle.

#### 💊 Common Drug Causes

💊 **PPIs**

\#1 cause\
Omeprazole, pantoprazole

Most Common 💉 **NSAIDs**

Prescription & OTC\
Ibuprofen, naproxen

Very Common 🦠 **Antibiotics**

β-lactams, sulfonamides\
Quinolones, rifampin

💧 **Diuretics**

Thiazides\
Loop diuretics

🛡️ **Checkpoint Inhibitors**

PD-1/PD-L1 inhibitors\
Rising incidence

Emerging

#### 🔬 Diagnostic Features

|              |                             |
|--------------|-----------------------------|
| Urine        | WBC casts, sterile pyuria   |
| Timeline     | Days to weeks post-exposure |
| FENa         | \>1% (tubular dysfunction)  |
| ⚠️ Urine Eos | NOT diagnostic (poor Sn/Sp) |

#### 💡 Management

1 **Stop offending drug** - First-line 2 **Wait 3-7 days** - Observe for recovery 3 **Steroids if no improvement**\
Prednisone 1 mg/kg/day × 2-4 weeks 4 **Biopsy** - If diagnosis uncertain

## 🧬 Acute Tubular Necrosis: Intrinsic Toxins

Endogenous nephrotoxins causing direct tubular injury through various mechanisms

### 💪 Rhabdomyolysis

- **Mechanism:** Myoglobin direct toxicity + tubular obstruction
- **Triggers:** Trauma, drugs, prolonged immobilization, exercise
- **Labs:** CK \>1000 U/L (often \>5000), myoglobinuria
- **Treatment:** Aggressive fluid resuscitation, alkalinization
- **Goal UOP:** 200-300 mL/hr initially
- **Key Point:** CK for detection, myoglobin causes actual injury

[💪 Complete Rhabdomyolysis Guide](https://urinenephrology.org/2025_UDPA_Lectures_Live/aki/rhabdo.html)

### 🩸 Hemolysis

- **Mechanism:** Free hemoglobin tubular toxicity
- **Causes:** Transfusion reactions, mechanical hemolysis
- **Labs:** ↓Haptoglobin, ↑LDH, hemoglobinuria
- **Clinical:** Dark red/brown urine
- **Management:** Treat underlying cause, maintain UOP

### 🧪 Light Chain Nephropathy

- **Setting:** Multiple myeloma, plasma cell disorders
- **Mechanism:** Light chain precipitation in tubules
- **Microscopy:** Large, fractured casts with angular edges
- **Diagnosis:** Serum/urine immunofixation, free light chains
- **Treatment:** Chemotherapy, plasmapheresis in severe cases

#### ⚡ Rhabdomyolysis Emergency Protocol

**🚰 Fluid Resuscitation**

- Normal saline 1-2 L/hr initially
- Goal UOP: 200-300 mL/hr
- Monitor for volume overload

**🧪 Alkalinization (Controversial)**

- Sodium bicarbonate in selected cases
- Goal urine pH \>6.5
- Avoid if volume overloaded

## 💊 Antibiotic-Associated Kidney Injury: Comprehensive Guide

Antibiotics represent one of the most common causes of drug-induced kidney injury in clinical practice

| Antibiotic Class | Primary Mechanism | Typical Onset (Days) | Pattern of Injury | Incidence Rate |
|----|----|----|----|----|
| **Aminoglycosides** | Direct tubular toxicity | 7-10 | Acute tubular necrosis | 10-25% |
| **Glycopeptides (Vancomycin)** | Oxidative stress, inflammasome activation | 5-10 | Acute tubular necrosis | 5-35% |
| **Beta-Lactams** | Hypersensitivity reaction | 10-14 | Acute interstitial nephritis | 1-3% |
| **Polymyxins** | Membrane damage | 5-7 | Acute tubular necrosis | 20-60% |
| **Fluoroquinolones** | Hypersensitivity reaction | 7-14 | Acute interstitial nephritis | \<1% |
| **Sulfonamides (Crystalluria)** | Crystal formation | 1-3 | Crystal nephropathy | 1-5% |
| **Tetracyclines** | Direct tubular toxicity | 3-7 | Fanconi syndrome | \<1% (modern agents) |
| **Macrolides** | Hypersensitivity, drug interactions | 7-14 | Acute interstitial nephritis | \<1% |
| **Amphotericin B** | Membrane damage | 5-7 | Acute tubular necrosis | 30-80% |

### 🧬 Aminoglycosides: Structure-Toxicity Relationship

**Key Concept:** Nephrotoxicity directly correlates with positive charge and number of amino groups

| Aminoglycoside | Relative Nephrotoxicity | Number of Amino Groups | Positive Charges | Clinical Notes |
|----|----|----|----|----|
| **Neomycin** | Highest (5/5) | 6 | +6 | Topical use only due to toxicity |
| **Gentamicin** | High (4/5) | 5 | +5 | Most commonly used, high efficacy |
| **Tobramycin** | Moderate to High (3/5) | 5 | +5 | Preferred for Pseudomonas |
| **Kanamycin** | Moderate (3/5) | 4 | +4 | Limited use due to resistance |
| **Amikacin** | Moderate (2/5) | 4 | +4 | Reserved for resistant organisms |
| **Netilmicin** | Low to Moderate (2/5) | 3 | +3 | Less nephrotoxic alternative |
| **Streptomycin** | Lowest (1/5) | 2 | +2 | Primarily ototoxic, less nephrotoxic |

#### 🔬 Mechanism of Charge-Related Toxicity

**1. Enhanced Membrane Binding**

Higher positive charge → stronger binding to negatively charged phospholipids in proximal tubular cells

**2. Increased Cellular Uptake**

More charges → greater megalin-mediated endocytosis → higher intracellular accumulation

**3. Enhanced Lysosomal Retention**

Highly charged molecules accumulate more in lysosomes → greater disruption of cellular function

**4. Mitochondrial Interference**

Greater positive charge → stronger binding to mitochondrial ribosomes → more energy disruption

### ⚖️ Vancomycin vs Aminoglycosides: Comparative Nephrotoxicity

| Aspect | Vancomycin | Aminoglycosides | Clinical Notes |
|----|----|----|----|
| **Overall AKI incidence** | 5-35% | 10-25% | Varies by definition and population |
| **Severe AKI requiring RRT** | 1-5% | 2-7% | Higher with prolonged therapy |
| **Time to AKI onset** | 5-10 days | 7-14 days | Vancomycin often earlier |
| **Persistent kidney dysfunction** | 5-15% | 10-20% | Higher with advanced age |
| **Concomitant use (both drugs)** | **35-45%** |  | Synergistic toxicity |
| **Primary mechanism** | NLRP3 inflammasome, oxidative stress | Lysosomal disruption, mitochondrial damage | Different subcellular targets |
| **Prevention strategy** | AUC-guided dosing | Extended-interval dosing | Both reduce toxicity significantly |

#### 🎯 Key Clinical Decision Points

- **Vancomycin + Piperacillin-Tazobactam:** 35-45% AKI risk (NNH = 8-10 patients)
- **Vancomycin + Aminoglycosides:** 25-40% AKI risk (avoid when possible)
- **AUC-guided vancomycin dosing:** 33-45% reduction in AKI risk
- **Extended-interval aminoglycosides:** 30-50% reduction in nephrotoxicity

## ⚠️ High-Risk Antibiotic Combinations

Synergistic nephrotoxicity from commonly used antibiotic combinations

### 🔥 Vancomycin + Piperacillin-Tazobactam

- **AKI Risk:** 21-40% (vs 8-13% vancomycin alone)
- **Mechanism:** Synergistic NLRP3 inflammasome activation
- **Risk Factors:** Age \>65, CKD, diabetes, high doses
- **Prevention:** AUC-guided vancomycin + extended-infusion pip-tazo
- **Alternatives:** Vancomycin + cefepime or meropenem

### ⚡ Vancomycin + Aminoglycosides

- **AKI Risk:** 25-40% (historic high-risk combination)
- **Mechanism:** Complementary nephrotoxic pathways
- **Risk Factors:** Higher doses, extended duration, pre-existing CKD
- **Management:** Avoid combination when possible
- **Monitoring:** Daily creatinine, enhanced biomarker surveillance

### 💀 Polymyxins + Vancomycin

- **AKI Risk:** 40-60% (extremely high-risk combination)
- **Mechanism:** Synergistic membrane damage + oxidative stress
- **Indication:** Extensively drug-resistant organisms only
- **Management:** Nephroprotective strategies, daily monitoring
- **Alternatives:** Consider newer agents when available

### 🚨 Triple Combination Therapy

- **AKI Risk:** 45-70% (vancomycin + aminoglycoside + beta-lactam)
- **Mechanism:** Multiple complementary nephrotoxic pathways
- **Risk Factors:** Nearly universal in high-risk patients
- **Management:** Avoid when possible, daily monitoring, early de-escalation
- **Rule:** Each additional nephrotoxin increases AKI odds by ~60%

### 🏭 Environmental & Heavy Metal Toxicity

#### ⚗️ Ethylene Glycol

- **Source:** Antifreeze ingestion
- **Mechanism:** Toxic metabolites (oxalic acid)
- **Timeline:** 6-12 hours post-ingestion
- **Treatment:** Fomepizole, hemodialysis
- **Lab findings:** Anion gap metabolic acidosis

#### 🔶 Heavy Metals

- **Mercury:** Proximal tubular necrosis
- **Lead:** Chronic tubulointerstitial disease
- **Cadmium:** Proximal tubular dysfunction
- **Treatment:** Chelation therapy (DMSA, EDTA)
- **Monitoring:** 24-hour urine metals

#### 🍄 Natural Toxins

- **Mushroom poisoning:** Amanita species
- **Snake venom:** Hemolysis, direct nephrotoxicity
- **Aristolochic acid:** Chinese herbs (chronic)
- **Treatment:** Supportive care, specific antidotes
- **Prevention:** Education, avoid herbal remedies

## 💎 Crystalopathy: Crystal-Induced Tubular Obstruction & AKI

**Pathophysiology:** Intratubular crystal precipitation causing mechanical obstruction, direct tubular toxicity, and acute kidney injury

#### 🔬 Common Crystalopathy Mechanisms

**📈 Supersaturation:**

- Exceed solubility limits in tubular fluid
- Concentration-dependent precipitation
- pH-dependent solubility (uric acid, cystine)
- Temperature effects on crystal formation

**🚰 Tubular Obstruction:**

- Mechanical blockage of tubular lumens
- Increased intratubular pressure
- Reduced effective filtration
- Secondary tubular cell injury

**💥 Direct Toxicity:**

- Crystal-induced inflammation
- Complement activation
- Reactive oxygen species generation
- Tubular epithelial cell death

### 🚨 Tumor Lysis Syndrome (TLS): Life-Threatening Uric Acid Crystalopathy

**Most dangerous crystalopathy** - requires immediate recognition and intervention within hours

#### ⚡ Critical Recognition Triad

**🧬 High-Risk Malignancy**

- Burkitt lymphoma (highest risk)
- High-grade NHL with bulky disease
- ALL/AML with high WBC count
- Recent chemotherapy initiation

**🧪 "Big Four" Lab Abnormalities**

- Hyperuricemia (\>8 mg/dL)
- Hyperkalemia (\>6.0 mEq/L)
- Hyperphosphatemia (\>4.5 mg/dL)
- Hypocalcemia (\<7.0 mg/dL)

**⏰ Critical Timeline**

- Peak risk: 12-72 hours post-chemo
- Hyperkalemia most immediately lethal
- Can progress to AKI requiring RRT
- Prevention superior to treatment

#### 💊 Emergency Management Priorities

**🚨 Immediate (0-1 hour):**

- Cardiac monitoring for hyperkalemia
- STAT electrolytes, uric acid, phosphorus
- G6PD testing if rasburicase planned
- Assess volume status

**⚡ Urgent (1-6 hours):**

- Hyperkalemia treatment if K+ \>6.5 mEq/L
- Rasburicase 0.2 mg/kg IV if indicated
- Aggressive hydration if not volume overloaded
- Nephrology consultation

**📊 Ongoing (6+ hours):**

- Serial electrolytes Q6-8h
- Monitor for AKI development
- Prepare for RRT if refractory
- Avoid calcium if PO4 \>6.5 mg/dL

#### 🎯 TLS Key Clinical Pearls

**🧬 Risk Stratification:**

- **Burkitt lymphoma:** Highest risk malignancy
- **High-grade NHL:** Risk increases with tumor burden
- **ALL/AML:** WBC \>50,000 or bulky disease
- **Timing:** Peak risk 12-72 hours post-chemo

**🩸 Rasburicase Pearls:**

- **Mechanism:** Converts uric acid → allantoin (water-soluble)
- **Contraindications:** G6PD deficiency (hemolysis risk)
- **Efficacy:** Uric acid normalizes within 4 hours
- **Monitoring:** Uric acid levels q6h

**⚠️ Critical Mistakes to Avoid:**

- **Calcium administration:** Risk of Ca-PO4 precipitation
- **Inadequate hydration:** Must achieve high UOP
- **Delayed recognition:** Monitor high-risk patients proactively
- **Urine alkalinization:** Not recommended (may worsen Ca-PO4)

**📊 Laboratory Monitoring:**

- **Baseline:** BMP, uric acid, phosphorus, LDH
- **Frequency:** Q6-8h x 72 hours minimum
- **AKI monitoring:** Daily creatinine, urine output
- **Response:** Uric acid should decline within 24h

#### ⚠️ TLS Prevention Strategies

**📊 Pre-Treatment Assessment:**

- Tumor burden assessment (CT, PET scan)
- Baseline electrolytes, uric acid, LDH
- G6PD testing if rasburicase anticipated
- Renal function and volume status

**💪 Prophylactic Measures:**

- Allopurinol 300mg daily x 1-2 days pre-chemo
- Aggressive hydration (3-4 L/day if tolerated)
- Rasburicase prophylaxis in very high-risk patients
- Consider modified chemotherapy regimen

**🕰️ Monitoring Protocol:**

- Electrolytes Q6h x 72 hours minimum
- Daily weights and strict I/O monitoring
- Continuous cardiac monitoring if K+ \>6.0
- Early nephrology involvement for high-risk cases

### 💎 Other Important Crystallopathies in AKI

Additional crystal-induced kidney injury patterns requiring specific recognition and management

#### 🎯 Uric Acid Crystalopathy (Non-TLS)

- **Causes:** Gout flares, dehydration, acidic urine (pH \<5.5)
- **Mechanism:** Uric acid precipitation in acidic tubular fluid
- **Recognition:** Yellow-brown needle-shaped crystals
- **Treatment:** Alkalinization (target pH 6.5-7.0), hydration
- **Prevention:** Allopurinol for chronic hyperuricemia

#### 🧡 Calcium Oxalate Crystalopathy

- **Causes:** Ethylene glycol poisoning, high-dose vitamin C
- **Mechanism:** Oxalate overproduction or ingestion
- **Recognition:** Envelope-shaped crystals, anion gap acidosis
- **Treatment:** Fomepizole (ethylene glycol), hemodialysis
- **Timeline:** AKI develops 6-12 hours post-ingestion

#### 💊 Drug-Induced Crystallopathy

- **Acyclovir:** Rapid IV infusion, dehydration
- **Sulfonamides:** Crystalluria in acidic urine
- **Methotrexate:** High-dose therapy, delayed excretion
- **Indinavir:** HIV protease inhibitor crystallopathy
- **Prevention:** Adequate hydration, appropriate infusion rates

#### ⚡ Calcium Phosphate Precipitation

- **Triggers:** Rapid calcium administration + high phosphate
- **Risk factors:** CKD, phosphate retention, alkalotic urine
- **Recognition:** Sudden AKI after calcium/phosphate administration
- **Prevention:** Avoid calcium if phosphate \>6.5 mg/dL
- **Clinical context:** Common complication in TLS management

#### 🔴 Cystine Crystalopathy

- **Cause:** Cystinuria (genetic defect in amino acid transport)
- **Recognition:** Hexagonal crystals, family history
- **Management:** Alkalinization (pH \>7.0), high fluid intake
- **Medications:** Tiopronin, penicillamine for stone prevention
- **Complication:** Recurrent nephrolithiasis and AKI

#### 🔬 2,8-Dihydroxyadenine Crystalopathy

- **Cause:** Adenine phosphoribosyltransferase (APRT) deficiency
- **Recognition:** Mimics uric acid stones, genetic testing
- **Treatment:** Allopurinol (blocks adenine metabolism)
- **Importance:** Often misdiagnosed as uric acid crystalopathy
- **Outcome:** Excellent response to allopurinol if recognized

#### 🎯 General Crystallopathy Management Principles

**💧 Hydration Strategies:**

- Target UOP 2-3 mL/kg/hr when possible
- Monitor for volume overload in CKD patients
- Consider loop diuretics if fluid retention
- Maintain euvolemia while maximizing clearance

**🧪 pH Management:**

- **Uric acid:** Alkalinize urine pH \>6.5
- **Cystine:** Alkalinize urine pH \>7.0
- **Calcium phosphate:** Avoid alkalinization
- **Monitor:** Urine pH q6h during treatment

**🔄 Prevention Strategies:**

- Identify high-risk patients early
- Prophylactic hydration for procedures
- Appropriate drug dosing and infusion rates
- Monitor for drug interactions affecting clearance

**⏱️ Monitoring Parameters:**

- Serial creatinine and urine output
- Urine microscopy for crystal identification
- Electrolyte panel q6-8h in acute phase
- Specific markers (uric acid, oxalate) as indicated

## 🏥 Contrast-Associated AKI (CA-AKI)

**Evolution from "Contrast-Induced":** Recognition of multifactorial pathogenesis beyond direct contrast toxicity

### ⚡ Risk Factors

- **Primary:** CKD (eGFR \<60), diabetes, volume depletion
- **Procedural:** High contrast volume, intra-arterial route
- **Patient:** Age \>75, heart failure, multiple myeloma
- **Concurrent:** Nephrotoxic medications, hypotension

### 🛡️ Prevention Strategies

- **Hydration:** Isotonic saline 1-1.5 mL/kg/hr × 6-12h
- **Contrast:** Minimize volume, use iso/low-osmolar agents
- **Medications:** Hold nephrotoxins, avoid NSAIDs
- **Timing:** Space procedures ≥48-72 hours apart

### 📊 Management Pearls

- **Timeline:** AKI develops 24-72h post-exposure
- **Peak:** Creatinine peaks at 3-5 days
- **Recovery:** Usually complete within 1-2 weeks
- **Monitoring:** Serial creatinine, urine output

## 🧮 AKI Assessment Tools

### Enhanced Drug Nephrotoxicity Risk

Age: 65 Baseline eGFR: 60 Primary Drug: High-Risk Combination: Duration of Therapy (days): 7 Volume Status: Calculating enhanced nephrotoxicity risk...

### KDIGO Staging Calculator

Baseline Creatinine (mg/dL): 1.0 Current Creatinine (mg/dL): 1.8 Patient Weight (kg): 70 Urine Output (mL/kg/hr): 0.8 Calculating KDIGO stage...

### Furosemide Stress Test

Patient Weight (kg): 70 Prior Furosemide Exposure: Urine Output Post-FST (mL): 180 Calculating FST interpretation...

### CA-AKI Risk Assessment

Age: 65 eGFR (mL/min/1.73m²): 45 Diabetes: Heart Failure: Calculating CA-AKI risk...

## 🗺️ AKI Diagnostic Flowchart

**1. RECOGNIZE AKI**\
↑Creatinine (≥0.3 mg/dL or 1.5× baseline) OR ↓UOP (\<0.5 mL/kg/hr × 6h) **2. ASSESS SEVERITY**\
KDIGO Staging + Check for life-threatening complications (hyperkalemia, acidosis, volume overload) **3. DETERMINE ETIOLOGY**\
History + Exam + Urine microscopy + Laboratory assessment + Imaging if indicated **4. INITIATE TREATMENT**\
Address underlying cause + Supportive care + Monitor for recovery vs progression **5. CONSIDER NEPHROLOGY CONSULTATION**\
Stage 2-3 AKI + Unclear etiology + Need for RRT + Complicated cases

### 🎯 Essential AKI Learning Points

#### 🚨 Emergency Recognition

- Anuria = nephrological emergency
- Check hyperkalemia immediately
- Foley catheter if obstruction suspected
- Fresh urine microscopy \<2 hours

#### 🔬 Diagnostic Essentials

- Urine microscopy differentiates causes
- FENa \<1% suggests prerenal
- Muddy brown casts = ATN
- RBC casts = glomerulonephritis

#### 🧪 Advanced Tools

- FST predicts progression/RRT need
- Superior to biomarkers
- KDIGO staging guides management
- CA-AKI is multifactorial

#### 💡 Clinical Pearls

- AKI-AKD-CKD continuum concept
- Prevention better than treatment
- Early nephrology consultation
- Monitor for recovery patterns

#### 🔥 Intrinsic Disease

- RPGN = nephrologic emergency
- Classic AIN triad rarely present
- Urine eosinophils NOT diagnostic
- Drug withdrawal first-line for AIN

#### 💊 Drug Nephrotoxicity

- Aminoglycosides: delayed onset (5-10 days)
- Vancomycin: trough level dependent
- PPIs most common cause of AIN
- Multiple nephrotoxins = exponential risk

## 🛡️ Multicomponent Kidney-Protection Strategy (KDIGO 2026 draft)

**Figure 9 — Escalating Prevention Bundle:** For patients at high risk through AKI Stage 3

1 **Discontinue all nephrotoxic agents when possible**

Review NSAIDs, aminoglycosides, contrast, ACEi/ARB in acute setting

2 **Optimize volume status and perfusion pressure**

Targeted resuscitation, avoid both hypo- and hypervolemia

3 **Consider advanced hemodynamic monitoring**

Especially in critically ill or hemodynamically unstable patients

4 **Frequently monitor functional (UOP, SCr) and structural biomarkers**

Serial assessment to detect progression early

5 **Check for changes in drug dosing**

Renally cleared medications require dose adjustment as GFR changes

6 **Diagnostic workup as appropriate**

Urine microscopy, imaging, serologies based on clinical context

7 **Consider RRT for persistent AKI or evolving indications**

Refractory hyperkalemia, acidosis, volume overload, uremic symptoms

**📌 Rec 3.2.3 (1B):** This bundle approach is formally recommended for high-risk surgical patients. KDIGO 2026 draft specifically recommends **AGAINST** isolated creatinine-based AKI alerts without systematic response strategies **(Rec 2.2.1, 1B)** — alerts must trigger this kind of structured response bundle.

## 💧 Fluid Management in AKI (KDIGO 2026 draft)

Updated evidence-based recommendations for volume resuscitation and hemodynamic targets

### 💉 Volume Resuscitation

Rec 3.1.1 · 1B

#### Crystalloids Over Colloids

Use **crystalloids over colloids** (albumin, gelatin, starches) for volume expansion in AKI risk or active AKI.

Rec 3.1.2 · 1B NEW

#### Buffered Crystalloids Preferred

**Buffered crystalloids (LR, Plasmalyte) over 0.9% NaCl** except in traumatic brain injury. This is a strong, new preference in KDIGO 2026 draft.

Rec 3.1.3 · 2C

#### Severe Metabolic Acidosis

pH \<7.20 → **IV bicarbonate over RRT** unless other urgent RRT indication exists.

Rec 3.1.4 · 1B

#### Liberal IV Fluids for Major Surgery

**Liberal IV fluids** (positive balance 1-2 kg at 24h) over restrictive (net zero) for elective major abdominal surgery.

**💡 Practical Note:** Oral rehydration is appropriate when IV access is not possible or practical.

### 🫀 Hemodynamic Targets

Rec 3.2.1 · 2C

#### MAP Target \>65 mmHg

Target MAP \>65 mmHg in critically ill patients. **Individualize:** higher for chronic HTN, lower for chronic hypotension.

Rec 3.2.2 · 1A AGAINST

#### No Low-Dose Dopamine

Recommend **AGAINST** low-dose dopamine for kidney protection. **Grade 1A** — strongest possible recommendation.

## ⚖️ Protein in AKI — Avoid Both Extremes

Neither protein restriction nor high-protein loading is appropriate. The evidence supports a balanced approach.

❌

#### Protein Restriction

- Worsens malnutrition and catabolism
- Does NOT prevent or delay RRT
- Does NOT preserve kidney function in AKI
- Increases muscle wasting in critical illness

**PP 3.9.2:** Do NOT restrict protein to prevent or delay RRT ⚖️

THE\
SWEET\
SPOT

Adequate protein to prevent catabolism without excessive load on injured kidneys

❌

#### High-Protein Loading

- No survival benefit (large pragmatic RCT)
- **Higher mortality** in AKI patients
- Longer time to hospital discharge
- Increases urea generation and uremic symptoms

**PP 3.9.3:** Do NOT push high protein (≥2.2 g/kg/day) in AKI

#### 📈 The High-Protein Harm Signal

A large pragmatic RCT compared high protein (≥2.2 g/kg/day) vs standard (≤1.2 g/kg/day). AKI patients randomized to high protein had:

- **Higher mortality**
- **Longer time to discharge**
- Increased urea generation → worsened uremic symptoms
- May accelerate the need for RRT

#### 🎯 Practical Guidance

- **Goal:** Adequate protein to prevent catabolism — not more
- **Caloric targets** do NOT change for AKI unless on RRT (PP 3.9.4)
- **On RRT:** Protein losses through dialysis circuit may require modest increase
- **Involve nutrition team** early for critically ill AKI patients
- **Monitor:** Prealbumin trends, nitrogen balance if available

**💡 Bottom Line:** Protein restriction does not protect injured kidneys. High-protein loading harms AKI patients. **Feed normally** — provide adequate calories and moderate protein to prevent catabolism without generating excessive urea load. This is one of those areas where “more is better” thinking gets patients in trouble.

## 📋 Post-AKI Follow-Up Care (KDIGO 2026 draft Chapter 6 — NEW)

Entirely new chapter in KDIGO 2026 draft — structured approach to AKI survivorship

Rec 6.1.1 · 1B

### 🤝 Coordinated Follow-Up

- All AKI/AKD survivors need **coordinated follow-up** with personalized care
- Clear transition of care with **identified healthcare professional**

**Discharge summaries must include:**

- AKI episode details
- Resolution status
- Medication management
- Follow-up plan

**📌 Risk stratify at discharge** using validated tools to guide follow-up intensity. PP 6.1.3

### 🩺 Post-AKI Comprehensive Assessment

🩸 **Blood Pressure** 💧 **Volume Status** 💊 **Medication Reconciliation** 🧪 **Kidney Function** 📊 **Albuminuria** Rec 6.2.1 · 1B

### 💊 Post-AKI Medications

**Start or Resume**

- **RASi** (ACEi/ARB) unless contraindicated
- Evaluate for **SGLT2i**
- Evaluate for **GLP-1 RA**
- Evaluate for **MRA**

**Timeline**

- Assess at **discharge**
- Reassess by **3 months**
- Monitor per KDIGO 2024 CKD guideline

### 🧬 CKD Evaluation

- Assess kidney function and damage markers **3 months after AKI/AKD**
- Use **cystatin C-based GFR** when SCr is less accurate (muscle wasting, critical illness recovery)

### 🏥 WATCH-ME Framework — Patients Discharged on Dialysis

W **Weight** & volume management A **Access** planning T **Treatment** prescription optimization C **Comorbidity** management H **Health literacy** & self-care M **Medication** reconciliation E **Education** & psychosocial support Rec 4.11.1 · 2D

### 🤒 Sick Day Protocols

Temporarily stop specific drugs during acute illness with volume depletion risk

ACEi / ARB Diuretics Metformin NSAIDs SGLT2i **⚠️ Critical:** Must include clear documented plan for medication **RESTART** **📚 Education:** Patient education on sick day rules is essential for safe self-management ⚠️

### KDIGO 2026 draft Alert Guidance (Rec 2.2.1, 1B)

Interruptive creatinine-based electronic alerts for AKI **in isolation**, WITHOUT systematic strategies for response, are recommended **AGAINST**. Alerts must trigger a **structured response bundle** (see Prevention Strategy above), not just a notification. An alert without a protocol is noise — an alert with a bundle saves kidneys.

## 📚 Sources

1.  Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138. [Official KDIGO guideline](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf).
2.  **Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network (AKIN).** Acute Kidney Injury Network: report of an initiative to improve outcomes in AKI. *Crit Care.* 2007;11(2):R31. [PMID: 17331245](https://pubmed.ncbi.nlm.nih.gov/17331245/). *— AKIN classification predecessor to KDIGO.*
3.  **STARRT-AKI Investigators; Bagshaw SM, Wald R, Adhikari NKJ, et al.** Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. *N Engl J Med.* 2020;383(3):240-251. [PMID: 32668114](https://pubmed.ncbi.nlm.nih.gov/32668114/). *— Accelerated vs standard KRT initiation; no mortality benefit, more dialysis dependence with accelerated.*
4.  **Gaudry S, Hajage D, Schortgen F, et al; AKIKI Study Group.** Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. *N Engl J Med.* 2016;375(2):122-133. [PMID: 27181456](https://pubmed.ncbi.nlm.nih.gov/27181456/). *— Early vs delayed RRT in ICU AKI.*
5.  **Rastogi R, Sheehan MM, Hu B, et al.** Treatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions. *JAMA Intern Med.* 2021;181(3):345-352. [PMID: 33369614](https://pubmed.ncbi.nlm.nih.gov/33369614/). *— Adjacent reference for inpatient antihypertensive intensification AKI risk (10.3% vs 7.9% propensity-matched).*
6.  **Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S.** Concurrent use of diuretics, ACE inhibitors, and ARBs with NSAIDs and risk of acute kidney injury. *BMJ.* 2013;346:e8525. [PMID: 23299844](https://pubmed.ncbi.nlm.nih.gov/23299844/). *— Triple-whammy paper; 487,372 patients; rate ratio 1.31 overall, 1.82 in first 30 days. Foundational drug-interaction AKI evidence.*

📚 For Educational Purposes Only

© 2025 Andrew Bland MD - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/aki/index.html) · Markdown synchronized October 3, 2026.